Back to Faculty
Faculty

Jennifer Chan

MD, MPH
Associate Professor of Medicine; Medical Oncologist
Dana-Farber Cancer Institute

Jennifer Chan, MD, MPH is an Associate Professor of Medicine at Harvard Medical School and an Institute Physician in the Division of Medical Oncology at Dana-Farber Cancer Institute in Boston, MA. She serves as the Director of the Program in Neuroendocrine and Carcinoid Tumors and the Clinical Director for the Gastrointestinal Cancer Center at the Dana-Farber/Brigham and Women's Cancer Center.

Dr. Chan focuses her clinical practice on the care of patients with neuroendocrine tumors and gastrointestinal cancers. She has been principal investigator of multiple clinical trials investigating novel therapies for neuroendocrine tumors. She serves on the National Comprehensive Cancer Network (NCCN) Neuroendocrine Tumors Guidelines Panel. She is a member of the Neuroendocrine Tumor Taskforce of the National Cancer Institute (NCI) and past President of the North American Neuroendocrine Tumor Society (NANETS).

2026 Sessions

Advancing Care in Extra-Pulmonary Neuroendocrine Carcinoma: Diagnosis, Treatment, and Emerging Therapies

This activity is supported by an independent medical educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.

Presenter

Sunday, September 27 10:50–11:35 AM
Gastrointestinal Cancers
Faculty

Jennifer Chan

MD, MPH
Associate Professor of Medicine; Medical Oncologist
Dana-Farber Cancer Institute

Jennifer Chan, MD, MPH is an Associate Professor of Medicine at Harvard Medical School and an Institute Physician in the Division of Medical Oncology at Dana-Farber Cancer Institute in Boston, MA. She serves as the Director of the Program in Neuroendocrine and Carcinoid Tumors and the Clinical Director for the Gastrointestinal Cancer Center at the Dana-Farber/Brigham and Women's Cancer Center.

Dr. Chan focuses her clinical practice on the care of patients with neuroendocrine tumors and gastrointestinal cancers. She has been principal investigator of multiple clinical trials investigating novel therapies for neuroendocrine tumors. She serves on the National Comprehensive Cancer Network (NCCN) Neuroendocrine Tumors Guidelines Panel. She is a member of the Neuroendocrine Tumor Taskforce of the National Cancer Institute (NCI) and past President of the North American Neuroendocrine Tumor Society (NANETS).
Back to top